Celldex Therapeutics (CLDX) Reports Q1 Loss, Lags Revenue Estimates

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of$ 0.75. This compares to loss of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -8%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.75 per share when it actually produced a loss of $0.71, delivering a surprise of 5.33%.Over the last four quarters, the c ...